cytarabine has been researched along with thalidomide in 46 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (26.09) | 29.6817 |
| 2010's | 31 (67.39) | 24.3611 |
| 2020's | 3 (6.52) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Estey, EH; Thall, PF | 1 |
| Albitar, M; Andreeff, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Thomas, D | 1 |
| Fanin, R; Geromin, A; Patriarca, F; Prosdocimo, S; Sperotto, A; Zaja, F | 1 |
| Bordone, J; Garcia, C; Milone, JH; Napal, J; Prates, V | 1 |
| McClain, KL | 1 |
| Czyzewski, K; Styczynski, J; Wysocki, M | 1 |
| Abidi, MH; Ibrahim, RB; Maria, D; Peres, E; Tove, I | 1 |
| Chen, YB; Fu, WJ; Hou, J; Wang, DX; Xi, H; Yuan, ZG | 1 |
| Barge, R; Bertsch, U; Blau, I; Bos, GM; Breitkreutz, I; Breitkreuz, I; Croockewit, S; de Weerdt, O; Delforge, M; Duersen, U; Goldschmidt, H; Joosten, P; Lokhorst, HM; Martin, H; Naumann, R; Salwender, HJ; Schaafsma, R; Scheid, C; Schlenzka, J; Schmidt-Wolf, I; Sinnige, H; Sonneveld, P; van der Holt, B; van Marwijk-Kooy, M; van Oers, MH; Vellenga, E; Verhoef, G; Wijermans, P; Wittebol, S; Zweegman, S | 1 |
| Gattermann, N; Germing, U; Giagounidis, A; Haas, R; Kobbe, G; Kündgen, A; Nachtkamp, K; Strupp, C | 1 |
| Santini, V | 1 |
| García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L | 1 |
| Byrne, GE; Coleman, F; Escalón, MP; Hosein, PJ; Lossos, IS; Morgensztern, D; Rosenblatt, JD; Walker, GR | 1 |
| Alba, L; Antinori, A; Bibas, M; Del Nonno, F; Grisetti, S; Picchi, G | 1 |
| Berthou, C; Eveillard, JR; Guillerm, G; Ianotto, JC; Tempescul, A | 1 |
| Kivivuori, SM; Nygaard, R | 1 |
| Adam, Z; Adamová, Z; Brejcha, M; Hájek, R; Kodet, R; Koukalová, R; Krejčí, M; Mayer, J; Moulis, M; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L | 1 |
| Gan, SL; Liu, YF; Meng, XL; Sun, H; Sun, L; Wan, DM; Zhou, JW | 1 |
| Geisler, CH | 1 |
| Alachkar, H; Becker, H; Bloomfield, CD; Blum, W; Byrd, JC; Caligiuri, MA; Dorrance, AM; Eiring, AM; Fehniger, TA; Garzon, R; Hickey, CJ; Lee, LJ; Maharry, K; Marcucci, G; Mishra, A; Mrózek, K; Nicolet, D; Perrotti, D; Radomska, HS; Santhanam, R; Schwind, S; Vij, R; Walker, A; Whitman, SP; Wu, LC; Wu, YZ; Zhao, X | 1 |
| Bocchia, M; Cencini, E; Defina, M; Fabbri, A; Fontanelli, G; Gozzetti, A; Mazzei, MA; Pietrini, A; Volterrani, L | 1 |
| Laurizohn, C; Machaczka, M | 1 |
| El Azeeim, HA; El Husseiny, NM; Kasem, N; Mattar, MW | 1 |
| Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K | 1 |
| Caraci, MR; Di Raimondo, F; Ferrara, F; Fuligni, F; Gazzola, A; Isidori, A; Laginestra, MA; Loscocco, F; Paolini, S; Piccaluga, PP; Pileri, SA; Riccardi, C; Rocchi, M; Rossi, M; Sparaventi, G; Visani, A; Visani, G | 1 |
| Tohyama, K | 1 |
| Wiernik, PH | 1 |
| Argnani, L; Maglie, R; Pellegrini, C; Pileri, S; Zinzani, PL | 1 |
| Cheah, CY; Seymour, JF; Wang, ML | 1 |
| Caballero, D; Canales, M; Dlouhy, I; González-Barca, E; López-Guillermo, A; Martín, A; Montes-Moreno, S; Ocio, EM; Redondo, AM; Salar, A | 1 |
| Brady, WE; Dickey, NM; Ford, LA; Griffiths, EA; L Bashaw, H; Sperrazza, J; Tan, W; Thompson, JE; Vigil, CE; Wang, ES; Wetzler, M | 1 |
| Gui, R; Li, M; Li, Z; Song, Y; Wei, X; Zhang, Y; Zhao, H; Zhou, J; Zu, Y | 1 |
| Liu, HB; Wang, W | 1 |
| Bakane, A; Balaji, R; Raj, R; Ramachandrakurup, S; Subburaj, D; Uppuluri, R | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Di Raimondo, F; Ferrara, F; Fuligni, F; Isidori, A; Loscocco, F; Paolini, S; Piccaluga, PP; Rocchi, M; Spina, E; Visani, A; Visani, G; Zammit, V | 1 |
| Chen, C; Xu, W; Yang, J | 1 |
| He, GL; He, SZ; Li, J; Xu, DR; Zou, WY | 1 |
| Ansai, SI; Hoashi, T; Ichiyama, S; Kanda, N; Komatsu, T; Nagai, K; Saeki, H; Yamada, Y | 1 |
| Barlogie, B; Mouhieddine, TH; Teruya-Feldstein, J | 1 |
| Ainley, L; Chavda, SJ; Cheesman, S; Counsell, N; Horder, J; Kyriakou, C; Lee, L; Mehta, A; Newrick, F; Papanikolaou, X; Popat, R; Rabin, N; Sive, J; Wechalekar, A; Yong, K | 1 |
| Alderuccio, JP; Alencar, AJ; Iyer, SG; Lossos, IS; Reis, IM; Rosenblatt, JD; Saul, EE | 1 |
7 review(s) available for cytarabine and thalidomide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug therapy for the treatment of Langerhans cell histiocytosis.
Topics: Anti-Inflammatory Agents; Antimetabolites; Brain Diseases; Cell Proliferation; Cladribine; Cytarabine; Drug Therapy, Combination; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Mercaptopurine; Practice Guidelines as Topic; Prednisone; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Thalidomide; Vinblastine | 2005 |
Autologous transplantation and management of younger patients with mantle cell lymphoma.
Topics: Age Factors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Management; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Remission Induction; Rituximab; Survival Analysis; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
Optimal therapy for adult patients with acute myeloid leukemia in first complete remission.
Topics: Adenine Nucleotides; Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Dose-Response Relationship, Drug; Humans; Interleukin-2; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Stem Cell Transplantation; Thalidomide; Treatment Outcome; Young Adult | 2014 |
Mantle Cell Lymphoma.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cytarabine; Drug Administration Schedule; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Staging; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Risk Factors; Rituximab; Thalidomide; Transplantation, Autologous | 2016 |
The VAD Scheme versus Thalidomide plus VAD for Reduction of Vascular Endothelial Growth Factor in Multiple Myeloma: A Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Humans; Microvessels; Multiple Myeloma; Thalidomide; Treatment Outcome; Vascular Endothelial Growth Factor A; Vincristine | 2018 |
10 trial(s) available for cytarabine and thalidomide
| Article | Year |
|---|---|
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Endothelial Growth Factors; Humans; Intercellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Liposomes; Lymphokines; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Prognosis; Survival Analysis; Thalidomide; Topotecan; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
[Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Constipation; Cytarabine; Dexamethasone; Disease-Free Survival; Fatigue; Follow-Up Studies; Humans; Leukopenia; Middle Aged; Multiple Myeloma; Remission Induction; Survival Rate; Thalidomide; Thrombocytopenia; Vincristine | 2007 |
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dexamethasone; Female; Humans; Male; Medical Oncology; Middle Aged; Multiple Myeloma; Remission Induction; Thalidomide; Thioguanine; Treatment Outcome; Vincristine | 2008 |
High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Remission Induction; Rituximab; Thalidomide; Treatment Outcome; Vincristine | 2010 |
Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Prospective Studies; Remission Induction; Thalidomide | 2014 |
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cisplatin; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Treatment Outcome; Young Adult | 2016 |
A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Thalidomide | 2016 |
Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Disease-Free Survival; Female; Gene Expression Profiling; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Thalidomide; Transcriptome; Treatment Outcome | 2017 |
Thalidomide in Combination with Chemotherapy in Treating Elderly Patients with Acute Myeloid Leukemia.
Topics: Aclarubicin; Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Outcome Assessment, Health Care; Proportional Hazards Models; Prospective Studies; Remission Induction; Thalidomide | 2018 |
R-MACLO-IVAM regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma - Long term follow up results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Methotrexate; Middle Aged; Progression-Free Survival; Prospective Studies; Remission Induction; Rituximab; Thalidomide; Vincristine; Young Adult | 2021 |
29 other study(ies) available for cytarabine and thalidomide
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
New designs for phase 2 clinical trials.
Topics: Acute Disease; Adenine Nucleotides; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bayes Theorem; Bias; Biomarkers; Clinical Trials, Phase II as Topic; Clofarabine; Confounding Factors, Epidemiologic; Cytarabine; Daunorubicin; Drug Carriers; False Negative Reactions; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid; Liposomes; Middle Aged; Patient Selection; Randomized Controlled Trials as Topic; Remission Induction; Research Design; Thalidomide; Topotecan; Treatment Outcome | 2003 |
Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Stem Cell Transplantation; Thalidomide; Vincristine | 2003 |
Response to single-agent thalidomide and eligibility to undergo autotransplant for patients with multiple myeloma refractory to VAD.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Patient Selection; Salvage Therapy; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2003 |
Ex vivo activity of thalidomide in childhood acute leukemia.
Topics: Angiogenesis Inhibitors; Cell Cycle; Child; Child, Preschool; Cytarabine; Female; Humans; Immunophenotyping; Infant; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Tetrazolium Salts; Thalidomide; Thiazoles | 2006 |
Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Histiocytes; Humans; Middle Aged; Prednisone; Retroperitoneal Neoplasms; Sarcoma; Thalidomide; Vincristine | 2007 |
Impact on survival of different treatments for myelodysplastic syndromes (MDS).
Topics: Adult; Aged; Antilymphocyte Serum; Cytarabine; Disease-Free Survival; Enzyme Inhibitors; Female; Germany; Humans; Immunosuppressive Agents; Male; Middle Aged; Myelodysplastic Syndromes; Registries; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Homologous; Valproic Acid | 2009 |
Is survival enough for myelodysplastic syndromes?
Topics: Adult; Aged; Antilymphocyte Serum; Cytarabine; Disease-Free Survival; Enzyme Inhibitors; Female; Germany; Humans; Immunosuppressive Agents; Male; Middle Aged; Myelodysplastic Syndromes; Registries; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Homologous; Valproic Acid | 2009 |
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine | 2010 |
Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Boronic Acids; Bortezomib; Cytarabine; Deoxycytidine; Dexamethasone; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; HIV Infections; Humans; Lenalidomide; Lymphoma, Large-Cell, Immunoblastic; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polyethylene Glycols; Pyrazines; Recombinant Proteins; Thalidomide; Young Adult | 2010 |
ESHAP chemotherapy regimen associated to lenalidomide induces complete isotopic remission in Hodgkin's lymphoma relapsing after autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lenalidomide; Prednisone; Recurrence; Remission Induction; Thalidomide; Transplantation, Autologous | 2011 |
Treatment for recurrent medulloblastoma with intrathecal liposomal cytarabine and systemic metronomic combination therapy.
Topics: Administration, Metronomic; Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cerebellar Neoplasms; Cytarabine; Etoposide; Humans; Injections, Spinal; Liposomes; Male; Medulloblastoma; Neoplasm Recurrence, Local; Neutropenia; Pyrazoles; Sulfonamides; Thalidomide; Treatment Outcome | 2012 |
[Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transp
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cladribine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Histiocytosis, Langerhans-Cell; Humans; Lenalidomide; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Thalidomide; Transplantation, Autologous | 2012 |
[Clinical observation of thalidomide combined with VAD regimen for treatment of osteosclerotic myeloma (POEMS syndrome)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Female; Humans; Male; Middle Aged; POEMS Syndrome; Retrospective Studies; Thalidomide; Vincristine | 2012 |
Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.
Topics: Adult; Animals; Antimetabolites, Antineoplastic; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Cytarabine; Frameshift Mutation; Gene Expression Regulation, Leukemic; Humans; Immunologic Factors; K562 Cells; Lenalidomide; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Neoplasm Proteins; Point Mutation; Promoter Regions, Genetic; Protein Isoforms; Protein Structure, Tertiary; Recombinant Fusion Proteins; RNA, Neoplasm; Thalidomide; Up-Regulation; Xenograft Model Antitumor Assays | 2013 |
Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Drugs, Investigational; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Immunologic Factors; Lenalidomide; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Organoplatinum Compounds; Polyethylene Glycols; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Vinblastine; Vinorelbine | 2013 |
Oral lesions in the course of myelofibrosis successfully treated using combination therapy with thalidomide, betamethasone, and cytarabine.
Topics: Aged; Betamethasone; Candida albicans; Cytarabine; Drug Therapy, Combination; Humans; Male; Oral Ulcer; Primary Myelofibrosis; Staphylococcus aureus; Thalidomide | 2013 |
Multiple myeloma: a descriptive study of 217 Egyptian patients.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Cytarabine; Dexamethasone; Egypt; Female; Hospitals, Urban; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Retrospective Studies; Severity of Illness Index; Thalidomide; Vincristine | 2014 |
Myeloma presenting during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous | 2014 |
Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
Topics: Allografts; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Carmustine; Combined Modality Therapy; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Liposomes; Male; Melphalan; Polyethylene Glycols; Recurrence; Remission Induction; Salvage Therapy; Thalidomide; Transplantation, Autologous; Young Adult | 2016 |
[Efficacy analysis of CAG priming regimen combined with talidomide, interferon and interleukin 2 as the induction therapy for relapsed refractory acute myeloid leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Interferons; Interleukin-2; Leukemia, Myeloid, Acute; Recurrence; Remission Induction; Thalidomide | 2016 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
[Efficacy Comparison of Low dose Thalidomide Combined with Modified VCMP and VAD regimens for Treatment of Aged MM Patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Humans; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Survival Rate; Thalidomide; Thrombocytopenia; Vincristine | 2016 |
Successful Treatment of Refractory Langerhans Cell Histiocytosis of the Choroid Plexus in a Child With Pulse Dexamethasone and Lenalidomide.
Topics: Choroid Plexus; Cladribine; Cytarabine; Dexamethasone; Diabetes Insipidus; Drug Resistance; Histiocytosis, Langerhans-Cell; Humans; Infant; Lenalidomide; Male; Pituitary Gland, Posterior; Prednisolone; Pulse Therapy, Drug; Remission Induction; Salvage Therapy; Skull Base; Thalidomide; Thoracic Vertebrae; Vinblastine | 2017 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
Treatment with apremilast was beneficial for chronic graft-versus-host disease skin lesion in a patient with psoriasis.
Topics: Administration, Oral; Biopsy; Bone Marrow Transplantation; Chronic Disease; Cytarabine; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Psoriasis; Skin; Thalidomide; Transplantation, Homologous; Treatment Outcome | 2019 |
Hemophagocytic relapsed intramedullary plasmacytoma.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Bortezomib; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Magnetic Resonance Imaging; Melphalan; Neoplasm Recurrence, Local; Oligopeptides; Plasmacytoma; Positron Emission Tomography Computed Tomography; Pubic Bone; Rare Diseases; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2020 |
DT-PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Progression-Free Survival; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Young Adult | 2021 |